Naturally acquired antibody kinetics against Plasmodium vivax antigens in people from a low malaria transmission region in western Thailand
Z. S.-J. Liu, J. Sattabongkot, M. White, S. Chotirat, C. Kumpitak, E. Takashima, M. Harbers, W.-H. Tham, J. Healer, C. E. Chitnis, T. Tsuboi, I. Mueller, R. J. Longley
Abstract
Plasmodium vivax is the dominant Plasmodium spp. causing the disease malaria in low-transmission regions outside of Africa. These regions often feature high proportions of asymptomatic patients with sub-microscopic parasitaemia and relapses. Naturally acquired antibody responses are induced after Plasmodium infection, providing partial protection against high parasitaemia and clinical episodes. However, previous work has failed to address the presence and maintenance of such antibody responses to P. vivax particularly in low-transmission regions. We followed 34 patients in western Thailand after symptomatic P. vivax infections to monitor antibody kinetics over 9 months, during which no recurrent infections occurred. We assessed total IgG, IgG subclass and IgM levels to up to 52 P. vivax proteins every 2-4 weeks using a multiplexed Luminex(R) assay, and identified protein-specific variation in antibody longevity. Generally, an increase in antibody level was observed within 1-week post symptomatic infection, followed by an exponential decay of different rates. We observed mostly IgG1 dominance and IgG3 sub-dominance in this population. IgM responses followed similar kinetic patterns to IgG, with some proteins unexpectedly inducing long-lived IgM responses. We also monitored antibody responses against 27 IgG-immunogenic antigens in 30 asymptomatic individuals from a similar region. Our results demonstrate that most antigens induced robust and long-lived total IgG responses following asymptomatic infections in the absence of (detected) boosting infections. Our work provides new insights into the development and maintenance of naturally acquired immunity to P. vivax and will guide the potential use of serology to indicate immune status and/or identify populations at risk.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comprehensive characterization of Plasmodium vivax antigens using a high-density peptide array
Rosita R. Asawa, Brittany Hazzard, … David Serre·bioRxiv·Mar 18, 2026
- Repeated Plasmodium vivax blood stage infection provides sterile protection against homologous challenge in non-human primates
N. Obaldia, J. L. da Silva Filho, … M. Marti·bioRxiv·Feb 13, 2023
- Development and validation of serological markers for detecting recent exposure to Plasmodium vivax infection
Rhea J. Longley, Michael T. White, … Ivo Mueller·bioRxiv·Nov 30, 2018
- Navigating parasite antigen genetic diversity in the design of Plasmodium vivax serological exposure markers for malaria
Paolo Bareng, Keliang Wu, … Rhea J. Longley·bioRxiv·Jul 7, 2025
- Impact of a rapid decline in malaria transmission on antimalarial IgG subclasses and avidity
I. Ssewanyana, J. Rek, … K. K. Tetteh·bioRxiv·Jun 26, 2020
- Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa
Saidou Balam, Kazutoyo Miura, … Myriam Arévalo‐Herrera·PLoS ONEPeer-reviewed·Mar 18, 2025